Sorrento Therapeutics (SRNE) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'SRNE	'
Entity Registrant Name	'Sorrento Therapeutics, Inc.	'
Entity Central Index Key	'0000850261	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	21,678,353

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$6,429,712	$5,091,312
Grants receivable	36,564	79,760
Prepaid expenses and other, net	407,560	80,918
Total current assets	6,873,836	5,251,990
Property and equipment, net	1,661,551	1,480,989
Intangibles, net	28,994,423	'
Other, net	452,805	48,625
Total assets	37,982,615	6,781,604
Current liabilities:	'	'
Accounts payable	1,407,516	439,533
Accrued payroll and related	808,568	77,744
Accrued expenses	102,387	66,896
Total current liabilities	2,318,471	584,173
Long-term debt	4,785,320	'
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued and outstanding	'	'
Common stock, $0.0001 par value; 750,000,000 shares authorized and 16,479,734 and 12,004,687 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	1,648	1,200
Additional paid-in capital	52,442,871	17,146,530
Deficit accumulated during the development stage	-21,565,695	-10,950,299
Total stockholders' equity	30,878,824	6,197,431
Total liabilities and stockholders' equity	$37,982,615	$6,781,604

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	16,479,734	12,004,687
Common stock, shares outstanding	16,479,734	12,004,687

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		92 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues:	'	'	'	'	'
Grant	$83,791	$134,506	$359,451	$461,790	$1,931,524
Collaboration and reimbursable research and development costs	'	'	'	'	223,453
Total revenues	83,791	134,506	359,451	461,790	2,154,977
Expenses:	'	'	'	'	'
Research and development	2,082,252	950,823	5,621,969	2,667,347	13,825,295
Acquired in-process research and development	'	'	1,210,000	'	1,210,000
General and administrative	1,114,621	427,030	3,752,233	890,262	8,323,626
Intangibles amortization	193,755	'	313,339	'	313,339
Total expenses	3,390,628	1,377,853	10,897,541	3,557,609	23,672,260
Loss from operations	-3,306,837	-1,243,347	-10,538,090	-3,095,819	-21,517,283
Interest expense	-51,285	'	-82,975	'	-82,975
Interest income	1,677	2,118	5,669	5,346	34,563
Net loss	($3,356,445)	($1,241,229)	($10,615,396)	($3,090,473)	($21,565,695)
Net loss per share - basic and diluted	($0.24)	($0.10)	($0.80)	($0.28)	'
Weighted average number of shares during the period - basic and diluted	14,135,261	11,963,699	13,303,581	11,210,899	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)

Total

June [Member]

September [Member]

December [Member]

May [Member]

IgDraSol Merger [Member]

Sherrington acquisition [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Stockholder Note Receivable [Member]

Accumulated Deficit during Development Stage [Member]

June [Member]

September [Member]

December [Member]

May [Member]

IgDraSol Merger [Member]

Sherrington acquisition [Member]

June [Member]

September [Member]

December [Member]

May [Member]

IgDraSol Merger [Member]

Sherrington acquisition [Member]

Balance at Jan. 25, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Jan. 25, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for $400 cash to founders

400

'

'

'

'

'

'

408

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

'

Issuance of common stock for $400 cash to founders, shares

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-75,801

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-75,801

Balance at Dec. 31, 2006

-75,401

'

'

'

'

'

'

408

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

-75,801

Balance, shares at Dec. 31, 2006

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Jan. 25, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with merger and acquisition

'

'

'

'

'

27,811,429

247,500

'

'

'

'

'

'

'

'

'

'

'

'

27,811,128

247,497

'

'

Net loss

-21,565,695

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Sep. 30, 2013

30,878,824

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2006

-75,401

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-75,801

Net loss

-16,302

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-16,302

Balance at Dec. 31, 2007

-91,703

'

'

'

'

'

'

408

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

-92,103

Balance, shares at Dec. 31, 2007

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-25,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-25,745

Balance at Dec. 31, 2008

-117,448

'

'

'

'

'

'

408

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

-117,848

Balance, shares at Dec. 31, 2008

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of restricted common stock for $291 cash to consultants in March

291

'

'

'

'

'

'

30

'

'

'

'

'

'

261

'

'

'

'

'

'

'

'

Issuance of restricted common stock for $291 cash to consultants in March, Shares

'

'

'

'

'

'

'

296,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for $10 cash and a $30 note to consultants in March

10

'

'

'

'

'

'

4

'

'

'

'

'

'

36

'

'

'

'

'

'

-30

'

Issuance of common stock for $10 cash and a $30 note to consultants in March, shares

'

'

'

'

'

'

'

40,775

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to former QuikByte stockholders in connection with the Merger

100,386

'

'

'

'

'

'

44

'

'

'

'

'

'

100,342

'

'

'

'

'

'

'

'

Issuance of common stock for cash

'

2,274,001

2,000,000

'

'

'

'

'

236

179

'

'

'

'

'

2,273,765

1,999,821

'

'

'

'

'

'

Issuance of common stock to former QuikByte stockholders in connection with the Merger, shares

'

'

'

'

'

'

'

442,958

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

'

'

'

'

'

'

'

'

2,360,611

1,785,375

'

'

'

'

'

'

'

'

'

'

'

'

'

Costs associated with the Merger

-168,767

'

'

'

'

'

'

'

'

'

'

'

'

'

-168,767

'

'

'

'

'

'

'

'

Stock-based compensation

54,524

'

'

'

'

'

'

'

'

'

'

'

'

'

54,524

'

'

'

'

'

'

'

'

Net loss

-942,266

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-942,266

Balance at Dec. 31, 2009

3,200,731

'

'

'

'

'

'

901

'

'

'

'

'

'

4,259,974

'

'

'

'

'

'

-30

-1,060,114

Balance, shares at Dec. 31, 2009

'

'

'

'

'

'

'

9,003,367

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collection of note receivable

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

Issuance of common stock for cash

'

'

'

3,440,495

'

'

'

'

'

'

102

'

'

'

'

'

'

3,440,393

'

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

'

'

'

'

'

'

'

'

'

'

1,028,686

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

250,954

'

'

'

'

'

'

'

'

'

'

'

'

'

250,954

'

'

'

'

'

'

'

'

Net loss

-1,808,386

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,808,386

Balance at Dec. 31, 2010

5,083,824

'

'

'

'

'

'

1,003

'

'

'

'

'

'

7,951,321

'

'

'

'

'

'

'

-2,868,500

Balance, shares at Dec. 31, 2010

'

'

'

'

'

'

'

10,032,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction of stock issuance costs accrued in December 2010

80,039

'

'

'

'

'

'

'

'

'

'

'

'

'

80,039

'

'

'

'

'

'

'

'

Repurchase of common stock

-43

'

'

'

'

'

'

-5

'

'

'

'

'

'

-38

'

'

'

'

'

'

'

'

Repurchase of common stock, shares

'

'

'

'

'

'

'

-44,166

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options

13,125

'

'

'

'

'

'

1

'

'

'

'

'

'

13,124

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

6,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

'

'

'

1,971,001

'

'

'

'

'

'

50

'

'

'

'

'

'

1,970,951

'

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

298,034

'

'

'

'

'

'

'

'

'

'

'

'

'

298,034

'

'

'

'

'

'

'

'

Net loss

-3,236,491

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,236,491

Balance at Dec. 31, 2011

4,209,489

'

'

'

'

'

'

1,049

'

'

'

'

'

'

10,313,431

'

'

'

'

'

'

'

-6,104,991

Balance, shares at Dec. 31, 2011

'

'

'

'

'

'

'

10,493,887

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options

36,092

'

'

'

'

'

'

1

'

'

'

'

'

'

36,091

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

10,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

'

'

'

'

5,934,031

'

'

'

'

'

'

150

'

'

'

'

'

'

5,933,881

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

863,127

'

'

'

'

'

'

'

'

'

'

'

'

'

863,127

'

'

'

'

'

'

'

'

Net loss

-4,845,308

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,845,308

Balance at Dec. 31, 2012

6,197,431

'

'

'

'

'

'

1,200

'

'

'

'

'

'

17,146,530

'

'

'

'

'

'

'

-10,950,299

Balance, shares at Dec. 31, 2012

'

'

'

'

'

'

'

12,004,687

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with merger and acquisition

'

'

'

'

'

27,811,429

247,500

'

'

'

'

'

301

3

'

'

'

'

'

27,811,128

247,497

'

'

Issuance of common stock in connection with the exercise of stock options

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

6,354,409

'

'

'

'

'

'

143

'

'

'

'

'

'

6,354,266

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

'

'

'

'

'

'

'

1,426,406

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with assignment agreement

40,000

'

'

'

'

'

'

1

'

'

'

'

'

'

39,999

'

'

'

'

'

'

'

'

Issuance of common stock in connection with assignment agreement, shares

'

'

'

'

'

'

'

10,000

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

Issuance of common stock warrants in connection with loan and security agreement

214,680

'

'

'

'

'

'

'

'

'

'

'

'

'

214,680

'

'

'

'

'

'

'

'

Stock-based compensation

621,771

'

'

'

'

'

'

'

'

'

'

'

'

'

621,771

'

'

'

'

'

'

'

'

Net loss

-10,615,396

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-10,615,396

Issuance of common stock in connection with merger and acquisition, shares

'

'

'

'

'

'

'

'

'

'

'

'

3,006,641

'

'

'

'

'

'

'

'

'

'

Balance at Sep. 30, 2013

$30,878,824

'

'

'

'

'

'

$1,648

'

'

'

'

'

'

$52,442,871

'

'

'

'

'

'

'

($21,565,695)

Balance, shares at Sep. 30, 2013

'

'

'

'

'

'

'

16,479,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) (USD $)	9 Months Ended	12 Months Ended						9 Months Ended
	Sep. 30, 2013	Dec. 31, 2009	Dec. 31, 2009	Dec. 31, 2009	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
	March [Member]	March [Member]	June [Member]	September [Member]	December [Member]	December [Member]	May [Member]	IgDraSol Merger [Member]	Sherrington acquisition [Member]
Proceeds from Issuance of restricted common stock to consultants	'	$291	'	'	'	'	'	'	'
Proceeds from Issuance of common stock to consultants	'	10	'	'	'	'	'	'	'
Proceeds from Issuance of common notes to consultants	'	30	'	'	'	'	'	'	'
Issuance of common stock per share	$4.50	'	$0.98	$1.12	$4	$3.50	$4	$9.25	$8.25
Common stock issuance cost	$64,086	'	$25,999	'	$28,999	$159,905	$65,969	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		92 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating activities	'	'	'
Net loss	($10,615,396)	($3,090,473)	($21,565,695)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'	'
Depreciation and amortization	637,648	209,038	1,116,337
Stock-based compensation	621,771	290,072	2,088,410
Non-cash interest expense	35,324	'	35,324
Changes in operating assets and liabilities, net of acquisition:	'	'	'
Grants receivable	43,196	-24,838	-36,564
Prepaid expenses and other	-348,421	-36,947	-457,815
Accounts payable	824,878	169,786	1,001,824
Accrued expenses and other liabilities	-477,452	15,119	-252,773
Net cash used for operating activities	-9,278,452	-2,468,243	-18,070,952
Investing activities	'	'	'
Purchases of property and equipment	-359,327	-491,096	-2,081,043
Purchase of intangible assets	-511,065	'	-511,065
Cash acquired in connection with Merger	125,835	'	230,695
Net cash used for investing activities	-744,557	-491,096	-2,361,413
Financing activities	'	'	'
Proceeds from issuance of common stock, net of issuance costs	6,354,409	5,934,031	21,805,860
Proceeds from exercise of stock options	7,000	4,200	56,217
Net borrowings under debt agreements	5,000,000	'	5,000,000
Net cash provided by financing activities	11,361,409	5,938,231	26,862,077
Net change in cash and cash equivalents	1,338,400	2,978,892	6,429,712
Cash and cash equivalents at beginning of period	5,091,312	3,466,549	'
Cash and cash equivalents at end of period	6,429,712	6,445,441	6,429,712
Cash paid during the period for:	'	'	'
Income taxes	800	800	5,600
Interest	$47,650	'	$47,650

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	1 Months Ended
	Jan. 31, 2013	Sep. 30, 2013
Number of shares issued for purchase of patent rights	10,000	'
Value of common stock issued for purchase of patent rights	$40,000	'
Issuance of common stock, shares	'	16,479,734
Issuance of common stock, value	'	1,648
Patent Rights [Member]	'	'
Number of shares issued for purchase of patent rights	10,000	'
Value of common stock issued for purchase of patent rights	40,000	'
IgDraSol Merger [Member]	'	'
Issuance of common stock, shares	'	3,006,641
Issuance of common stock, value	'	27,811,429
Sherrington Pharmaceuticals, Inc. [Member]	'	'
Issuance of common stock, shares	'	30,000
Issuance of common stock, value	'	$247,500

Nature_of_Operations_Summary_o

Nature of Operations, Summary of Significant Accounting Policies and Business Activities	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Nature of Operations, Summary of Significant Accounting Policies and Business Activities	'
	1. Nature of Operations, Summary of Significant Accounting Policies and Business Activities
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc., together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the United States, Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including inflammation, metabolic disorders, and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor, as well as fully human therapeutic antibodies derived from our proprietary G-MAB® library platform and antibody drug conjugates, or ADCs, antibody formulated drug conjugates, or AfDCs, and recombinant intravenous immunoglobulin, or rIVIG. See Note 7.
	Through September 30, 2013, the Company had devoted substantially all of its efforts to product development, acquiring companies and in-licensing assets, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with generally accepted accounting principles in the U.S., or GAAP.
	The balance sheet at December 31, 2012 is derived from the audited consolidated balance sheet at that date which is not presented herein.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2013 fiscal year.
	Reverse Stock Split
	On July 30, 2013, the Company completed a 1-for-25 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action.
	Business Activities
	On September 21, 2009, QuikByte Software, Inc., a shell company (QuikByte) acquired Sorrento Therapeutics, Inc., a privately held Delaware corporation (STI), in a reverse merger (the “Reverse Merger”). Pursuant to the Reverse Merger, all of the issued and outstanding shares of STI common stock were exchanged into an aggregate of 6,775,032 shares of QuikByte common stock and STI became a wholly owned subsidiary of QuikByte. The holders of QuikByte’s common stock as of immediately prior to the Reverse Merger held an aggregate of 2,228,332 shares of QuikByte’s common stock. STI and QuikByte reincorporated in Delaware in December 2009, and on December 4, 2009, STI merged with and into QuikByte, the separate corporate existence of STI ceased and QuikByte continued as the surviving corporation. Contemporaneously, QuikByte Software, Inc. changed its name to Sorrento Therapeutics, Inc. In connection with the Reverse Merger, the Company received cash of $104,860.
	In January 2013, the Company entered into an assignment agreement (the “assignment agreement”) with Tien-Li Lee, M.D. and Jane Wu Lee, M.D. as individuals (collectively, the “Lees”) pursuant to which the Lees agreed to assign to the Company their right, title and interest throughout the world in and to certain inventions and patents that provide for the production of recombinant intravenous immunoglobulins. See Note 2.
	On March 7, 2013, the Company entered into various agreements with IgDraSol, Inc. (“IgDraSol”) a private company focused on the development of Cynviloq, an oncologic agent for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers, as follows: (i) an exclusive option agreement, (ii) an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies, and (iii) an initial services agreement, pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform. See Note 3.
	Liquidity
	As reflected in the accompanying consolidated financial statements, the Company has incurred operating losses since its inception in 2006, and as of September 30, 2013, had an accumulated deficit of $21,565,695. At September 30, 2013, the Company had working capital of $4,555,365.
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) advances its CynviloqTM asset into a registration trial (a single bioequivalence study) and pursues other potential indications, (ii) acquires Sherrington Pharmaceuticals, Inc., or Sherrington, and advances its pain drug into clinical trials, (iii) continues to identify and advance a number of fully human therapeutic antibody and ADC preclinical drug candidates, (iv) acquires Concortis Biosystems, Corp., or Concortis, and (v) expands its corporate infrastructure, including the costs associated with being a public company. See Note 7.
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. Contemporaneously with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. In October 2013, the Company: (i) closed an underwritten public offering of 4,772,500 shares of its common stock, including the Underwriters exercise of an over-allotment of 622,500 shares of common stock, at $7.25 per share and total gross proceeds of $34.6 million, and (ii) issued an aggregate $1,850,000 principal amount of Convertible Promissory Notes (the “Notes”) that bear interest at 7% per annum. Such Notes and related accrued interest automatically converted into 256,119 shares of common stock at $7.25 per share effective in October 2013. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months. See Note 7.
	The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the October 2013 underwritten offering, the Company has the ability to offer up to $65.4 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
	Principles of Consolidation
	The financial statements also include the accounts of the Company’s wholly-owned subsidiaries, IgDraSol, Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong. Sorrento Hong Kong had no operating activity through September 30, 2013. All inter-company balances and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. Such adjustments could include, for example, appropriate estimates for Company bonus plans normally determined or settled at year-end.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2013 and December 31, 2012, the carrying amount of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Grants Receivable
	Grants receivable at September 30, 2013 and December 31, 2012 represent amounts due under federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health (“NIH”), collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
	Property and Equipment
	Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Such lives vary from three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset.
	Intangibles
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. The Company had no patent rights as of December 31, 2012. Amortization expense for the three and nine months ended September 30, 2013 was $1,250 and $2,500, respectively, which has been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. The Company had no licenses rights as of December 31, 2012. Amortization expense for the three and nine months ended September 30, 2013 was $110,839, which has been included in intangibles amortization.
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through September 30, 2013.
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually.
	Revenue Recognition
	The Company’s revenues are generated from the NIH and U.S. Treasury grant awards and a feasibility study agreement, or the Collaboration Agreement, that the Company entered into with a third party in July 2010. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	The revenue from the Collaboration Agreement is derived from the completion of certain development services and the reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue.
	Research and Development Costs and Collaborations
	Research and development costs are charged to expense as incurred. Such costs primarily consist of discovery research, pre-clinical activities, manufacture of drug supply, lab supplies, contract and acquired services, stock-based compensation expense, salaries and related benefits, depreciation and allocated and direct facility expenses.
	The Company evaluates its collaborative agreements for proper income statement classification based on the nature of the underlying activity. If payments to collaborative partners are not within the scope of other authoritative accounting literature, the income statement classification for these payments is based on a reasonable, rational analogy to authoritative accounting literature that is applied in a consistent manner. Amounts due to collaborative partners related to development activities are reflected as a research and development expense.
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.
	Stock-based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity-based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at estimated fair value as they vest.
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the three or nine months ended September 30, 2013 and 2012 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. The Company had outstanding common share equivalents of 551,850 and 460,668 at September 30, 2013 and 2012, respectively. The Company excludes the potential issuance of common shares contingently issuable to the Lees or IgDraSol as there is no guarantee that such shares will be issued in the future. See Notes 2 and 3.
	New Accounting Standards
	In July 2012, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update, or ASU, 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment (the revised standard). The objective of this ASU is to simplify how entities test indefinite-lived intangible assets other than goodwill for impairment. The amendments in the ASU provide the option to first assess qualitative factors to determine whether, as a result of its qualitative assessment, that it is more-likely-than-not (a likelihood of more than 50%) the asset is impaired and it is necessary to calculate the fair value of the asset in order to compare that amount to the carrying value to determine the amount of the impairment, if any. If an entity believes, as a result of its qualitative assessment, that it is not more-likely-than-not (a likelihood of more than 50%) that the fair value of an asset is less than its carrying amount, no further testing is required. The revised standard includes examples of events and circumstances that might indicate that the indefinite-lived intangible asset is impaired. The approach in the ASU is similar to the guidance for testing goodwill for impairment contained in ASU 2011-08, intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment. The revised standard, which may be adopted early, is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012 and does not change existing guidance on when to test indefinite-lived intangible assets for impairment. The adoption of the provisions of this guidance is not expected to have a material impact on the Company’s consolidated results of operations, cash flows, and financial position.

Significant_Agreements_and_Con

Significant Agreements and Contracts	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Significant Agreements and Contracts	'
	2. Significant Agreements and Contracts
	License Agreement with OPKO Health, Inc.
	In June 2009, the Company entered into a limited license agreement, or the OPKO License, with OPKO Health, Inc., or OPKO, pursuant to which the Company granted OPKO an exclusive, royalty-free, worldwide license under all U.S. and foreign patents and patent applications owned or controlled by the Company or any of its affiliates, or the STI Patents, to: (i) develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of drugs for ophthalmological indications, or the OPKO Field, and (ii) use and screen any population of distinct molecules covered by any claim of the STI Patents or which is derived by use of any process or method covered by any claim of the STI Patents to identify, select and commercialize certain products within the OPKO Field. Subject to certain limitations, OPKO will have the right to sublicense the foregoing rights granted under the OPKO License. Additionally, pursuant to the OPKO License, OPKO has granted the Company an exclusive, royalty-free, worldwide license to any patent or patent application owned or controlled by OPKO or any of its affiliates to develop, use, make, market, sell and distribute certain products in any field of use, other than the OPKO Field, or the OPKO Patents.
	The Company has retained all rights to the STI Patents outside of the OPKO Field and has agreed not to practice the OPKO Patents or the STI Patents outside the STI current field of use. Unless otherwise terminated in accordance with its terms, the License Agreement will expire upon the expiration of the last to expire patent within the STI Patents and OPKO Patents on a country-by-country basis.
	License Agreement with The Scripps Research Institute
	In January 2010, the Company entered into a license agreement, or the TSRI License, with The Scripps Research Institute, or TSRI. Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus (“Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved, (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For the three months ended September 30, 2013 and 2012 and for the period from inception (January 25, 2006) (“Inception”) through September 30, 2013, the Company recorded $13,418, $5,293 and $147,570 in patent prosecution and maintenance costs associated with the TSRI License, respectively. For the nine months ended September 30, 2013 and 2012, the Company recorded $20,225 and $27,861 in patent prosecution and maintenance costs associated with the TSRI License, respectively. All such costs have been included in general and administrative expenses.
	License Agreement with B.G. Negev Technologies and Applications Ltd.
	In July 2013, the Company entered into an exclusive option agreement with B.G. Negev Technologies and Applications Ltd. (“BGN”). Pursuant to the terms of the option agreement, BGN granted the Company an option to receive an exclusive sub-licensable worldwide license in and to certain licensed patent rights to develop and commercialize the licensed products. Licensed patent rights refers to any rights arising out of or resulting from any patent application filed by the Company for certain BGN technology relating to a group of defined fully human antibodies that bind to a Hep. C protease enzyme.
	NIH Grants
	In May 2010, the NIAID awarded the Company an Advanced Technology Small Business Technology Transfer Research grant to support the Company’s program to generate and develop novel antibody therapeutics and vaccines to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant award. The project period for the Staph Grant award covers a two-year period which commenced in June 2010, with a potential award of $300,000 per year. As of December 31, 2012, the entire Phase 1 grant of $600,000 had been awarded and recognized as revenue. The Company records revenue associated with the grant as the related costs and expenses are incurred. During the three and nine months ended September 30, 2012, and for the period from Inception through September 30, 2013, the Company recorded $0, $119,379 and $600,000 of revenue associated with the Staph Grant award, respectively.
	In July 2011, the NIAID awarded the Company a second Advanced Technology Small Business Technology Transfer Research grant, with an initial award of $300,000, to support the Company’s program to generate and develop antibody therapeutics and vaccines to combat C. difficile infections, or the C. difficile Grant award. The project period for the C. difficile Grant award covers a two-year period which commenced in June 2011, and as of September 30, 2012, the entire Phase 1 grant of $600,000 had been awarded. During the three months ended September 30, 2013 and 2012, and for the period from Inception through September 30, 2013, the Company recorded $0, $94,707 and $592,717 of revenue associated with the C. difficile Grant award, respectively. During the nine months ended September 30, 2013 and 2012, the Company recorded $143,940 and $265,811 of revenue associated with the C. difficile Grant award, respectively.
	In June 2012, the NIAID awarded the Company a third Advanced Technology Small Business Technology Transfer Research grant, with an initial award of $300,000, to support the Company’s program to generate and develop novel human antibody therapeutics to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant II award. The project period for the phase I grant covers a two-year period which commenced in June 2012, with a potential annual award of $300,000 per year. During the three months ended September 30, 2013 and 2012, and for the period from Inception through September 30, 2013, the Company recorded $83,791, $39,799 and $344,328, respectively, of revenue associated with the Staph Grant II award. During the nine months ended September 30, 2013 and 2012, the Company recorded $215,512 and $39,799 of revenue associated with the Staph Grant II award, respectively.
	Collaboration Agreement
	In July 2010, the Company entered into the Collaboration Agreement with a third party. Under the terms of the Collaboration Agreement, the Company provided certain antibody screening services for an upfront cash fee of $200,000 and was reimbursed for certain costs and expenses associated with providing the services, or the Development Costs. The upfront fee and reimbursable Development Costs were accounted for as separate units of accounting. The Company recorded the gross amount of the reimbursable Development Costs as revenue and the costs associated with these reimbursements are reflected as a component of research and development expense.
	Any amounts received by the Company pursuant to the Collaboration Agreement prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue. All agreed upon services under the Collaboration Agreement were delivered in March 2011. For the period from Inception through September 30, 2013, the Company recognized $223,453 in revenue.
	U.S. Treasury Grants
	During 2010, the U.S. Treasury awarded the Company grants totaling $394,480 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The proceeds from this grant are classified in “Revenues – Grant” for the period from Inception through September 30, 2013.
	Assignment Agreement
	In January 2013, the Company entered into the assignment agreement, pursuant to which the Lees agreed to assign to the Company their right, title and interest throughout the world in and to certain inventions and patents that provide for the production of recombinant intravenous immunoglobulin. As consideration for the assignment by the Lees under the assignment agreement, the Company: (i) issued the Lees 10,000 shares of the Company’s common stock upon execution of the assignment agreement, (ii) paid the Lees $50,000 in five monthly installments of $10,000 beginning on February 1, 2013, and (iii) agreed to issue the Lees up to 80,000 shares of the Company’s common stock based upon the achievement of certain milestone events described in the assignment agreement. Unless otherwise terminated in accordance with its terms, the assignment agreement will expire upon the expiration of the last to expire patent within the assigned patent rights.

IgDraSol_Transactions_and_Acqu

IgDraSol Transactions and Acquisition	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
IgDraSol Transactions and Acquisition	'
	3. IgDraSol Transactions and Acquisition
	On March 7, 2013, the Company entered into an exclusive option agreement with IgDraSol, a private company focused on the development of oncologic agents for the treatment of MBC, NSCLC, and other cancers. IgDraSol granted the Company an irrevocable option to acquire IgDraSol by means of an agreement and plan of merger, and was paid a non-refundable lump sum payment of $200,000 in April 2013. Such payment was capitalized and amortized in full over the life of the option period as intangibles amortization as of September 30, 2013.
	The Company entered into an initial services agreement dated March 7, 2013 with IgDraSol, wherein IgDraSol provided certain product development and technology services related to antibody-based nanotherapeutics. In March 2013, IgDraSol was paid a non-refundable payment of $1,000,000 and the related services were completed prior to May 31, 2013. In addition, the Company entered into an asset purchase agreement with IgDraSol whereby it agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies for a purchase price of $1,210,000. The purchase price was paid in April 2013 and was recognized as acquired in-process research and development expense. Also in April 2013, the Company entered into a development services agreement with IgDraSol related to the development of Tocosol® and related technologies. For the three and nine months ended September 30, 2013, the Company recorded $875,133 and $1,721,193, respectively, of operating expenses associated with the development services agreement.
	On September 9, 2013, the Company exercised its option to acquire IgDraSol whereby IgDraSol became a wholly-owned subsidiary. Pursuant to the merger agreement, the Company issued 3,006,641 shares of common stock to IgDraSol stockholders and paid $0.4 million in cash. Upon the later achievement of a specified regulatory milestone, the Company will issue an additional 1,306,272 shares of common stock to former IgDraSol stockholders.
	The following tables summarize the consideration transferred to acquire IgDraSol and the amounts of identified assets acquired and liabilities assumed at the acquisition date.
	The purchase price is summarized as follows:
		(in thousands)
	Cash buyout of certain holders of IgDraSol common stock options and warrants	$	356.1
	Market value of shares of Sorrento common stock issued in exchange for IgDraSol common stock		27,811.40
	Transaction fees, including separation and bonus payments of $771,000 made to IgDraSol employees		937.8
	Total purchase price	$	29,105.30
	The purchase price has been allocated based on the fair value of assets acquired and liabilities assumed ($ in thousands):
	Assets acquired:
	Cash	$	125.8
	Prepaid expenses & other		44.9
	PP&E		120.9
	Intangible license rights		29,105.30
	Total assets		29,396.90
	Liabilities assumed:
	Accounts payable		167.7
	Accrued expenses		123.9
	Total liabilities		291.6
	Total purchase price	$	29,105.30
	The intangible license rights will be amortized through fiscal 2028 at an annual rate of $1,900,093.

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt	'
	4. Debt
	Equipment Loan and Security Agreement
	In February 2013, the Company entered into an equipment loan and security agreement with a bank pursuant to which the lender provided the Company a loan in the principal amount of $875,888 to finance certain equipment. Interest accrues on the outstanding advance at the fixed rate of 5.15%. The Company granted the lender a security interest in any equipment that is financed under the equipment loan agreement. In September 2013, the equipment loan was paid in full, the Company had no further obligations thereunder, and the bank released its security interest in such assets.
	Loan and Security Agreement
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, or the Term Loan, which was funded at closing. The interest rate on the Term Loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until November 1, 2014, after which equal monthly payments of principal and interest are due. The maturity date of the Term Loan is April 15, 2017. The Term Loan is secured by a security interest in all of the Company’s assets except intellectual property. The Company’s intellectual property is subject to a negative pledge. In connection with the Term Loan, the Lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The value of the warrants, totaling $214,680, was recorded as debt discount and additional paid-in capital in the consolidated balance sheet as of September 30, 2013.
	At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay a final fee of $200,000.
	The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt. In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.
	Future annual principal payments under the loan agreement, as of September 30, 2013, are as follows:
	2014	$	303,406
	2015		1,907,040
	2016		2,064,298
	2017		725,256
	Debt discount		(214,680	)
	Long-term debt	$	4,785,320

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	5. Stockholders’ Equity
	Common Stock and Related Party Transaction
	In December 2011, the Company entered into a Stock Purchase Agreement, or the Stock Purchase Agreement, and issued 500,000 shares of common stock in a private placement transaction at $4.00 per share, for aggregate gross proceeds of $2,000,000. In May 2012, the Company entered into an Amended and Restated Stock Purchase Agreement, and issued 1,500,000 shares of common stock in a private placement transaction at $4.00 per share, for aggregate gross proceeds of $6,000,000. Two hundred and fifty thousand of the shares were purchased by an investor, Hongye SD Group, LLC, of which Dr. Henry Ji, the Company’s Chief Executive Officer and President, is a managing director.
	In January 2013, the Company entered into the assignment agreement and issued 10,000 shares of common stock valued at $40,000.
	In March 2013, the Company entered into a Stock Purchase Agreement and issued 1,426,406 shares of common stock, in a private placement transaction, at $4.50 per share for aggregate gross proceeds of $6,418,495.
	In April 2013, Company’s stockholders approved, among other items, three amendments to the Company’s Certificate of Incorporation, as follows: (i) increased the number of shares of common stock authorized to be issued by the Company from 500,000,000 to 750,000,000, (ii) authorized the Company’s Board of Directors, or the Board, to effect a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-2 and not more than 1-for-150, with the Board having the discretion as to whether or not the reverse split is to be effected at any time prior to April 26, 2014, and (iii) authorized the Board, in the event a reverse stock split is approved, in its discretion, to reduce the number of shares of common stock authorized to be issued by the Company in proportion to the percentage decrease in the number of outstanding shares of common stock resulting from the reverse split (or a lesser decrease in authorized shares of common stock as determined by the Board in its discretion). See Note 1.
	Stock Incentive Plans
	2009 Equity Incentive Plan
	In February 2009, prior to the Merger, the Company’s Board of Directors approved the 2009 Equity Incentive Plan, or the EIP, under which 400,000 shares of common stock were reserved for issuance to employees, non-employee directors and consultants of the Company. In March 2009, the Company issued 296,155 restricted common stock awards to certain consultants for aggregate gross proceeds of $291, of which the Company repurchased 44,166 unvested shares of restricted common stock for $43 in January 2011. The restricted shares vested monthly over four years and all remaining shares were fully vested as of September 30, 2013. No further shares are available for grant under the EIP.
	2009 Non-Employee Director Grants
	In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 nonstatutory stock options to the Company’s non-employee directors. The outstanding options vested on the one year anniversary of the vesting commencement date in October 2010. Such options are exercisable on the two year anniversary of the grant date and are generally exercisable for up to 10 years from the grant date. No further shares may be granted under this plan and, as of September 30, 2013, 3,200 options were outstanding.
	2009 Stock Incentive Plan
	In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In April 2013, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan, or the Stock Plan, to increase the number of common stock authorized to be issued pursuant to the Stock Plan to 1,360,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. In addition, this amount will be automatically increased annually on the first day of each fiscal year by the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 200,000 shares, or (iii) an amount approved by the administrator of the Stock Plan. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants will generally vest 25% on each anniversary of the original vesting date over four years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of the Company’s common stock issued in connection with an early exercise however, may be repurchased by the Company upon termination of the optionee’s service with the Company.
	During the nine months ended September 30, 2013 and 2012, the Company’s Board of Directors awarded 110,200 and 325,200 options to certain employees and consultants and 833,400 and 147,800 shares were available for grant under the Stock Plan, respectively.
	The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock based compensation expense is recognized over the vesting period using the straight-line method. The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Nine months ended September 30,
		2013			2012
	Dividend yield		—		—
	Volatility		109	%	102%
	Risk-free interest rate		1.19	%	0.71% - 1.11%
	Expected life of options		6.1 years		5.6 years
	The weighted average grant date fair value per share of employee stock options granted during the nine months ended September 30, 2013 and 2012 was $4.78 and $3.25, respectively.
	The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the United States Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.
	The total employee stock-based compensation recorded as operating expenses was $157,853, $20,685 and $873,140 for the three months ended September 30, 2013 and 2012 and for the period from Inception through September 30, 2013, respectively. The total employee stock-based compensation recorded as operating expenses was $454,324 and $75,350 for the nine months ended September 30, 2013 and 2012, respectively.
	As of September 30, 2013, unrecognized compensation cost related to the options was $1,654,334 which will be recognized over 2.9 years.
	The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the applicable authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $34,254, $66,130 and $1,215,270 for the three months ended September 30, 2013 and 2012 and for the period from Inception through September 30, 2013, respectively. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $167,447 and $214,722 for the nine months ended September 30, 2013 and 2012, respectively.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	6. Income Taxes
	The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development. The net deferred tax asset has been fully offset by a valuation allowance because of the Company’s history of losses. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	7. Subsequent Events
	Agreement and Plan of Merger – Sherrington
	On October 9, 2013, the Company and SP Merger Sub, Inc., a wholly owned subsidiary of the Company, Sherrington Pharmaceuticals, Inc. and the stockholders of Sherrington (the “Sherrington Holders”) entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”) pursuant to which the Company issued an aggregate of 200,000 shares of its common stock to the Sherrington Holders (the “Merger Shares”) and SP Merger Sub was merged into Sherrington (the “Merger”). Pursuant to the Agreement, 29,350 of the Merger Shares are being held in escrow for any potential indemnification claims. The Company filed a resale registration statement on Form S-3 with the Securities and Exchange Commission on October 31, 2013 to register the Merger Shares.
	Underwritten Public Offering and Nasdaq Uplisting
	Underwritten Public Offering of Common Stock
	On October 30, 2013, the Company closed an underwritten public offering of 4,150,000 shares of common stock, at $7.25 per share, and closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 622,500 shares of its common stock, with total gross proceeds of $34.6 million, before underwriting discounts and commissions and other offering expenses payable by the Company. The common stock began trading on The NASDAQ Capital Market on October 25, 2013 under the symbol “SRNE”.
	Purchase Warrants
	Concurrent with the offering, the Company agreed to issue and sell to the underwriters a warrant (“Underwriters Warrant”) for the purchase of an aggregate of 182,600 shares of Common Stock, representing 4.4% of the Firm Shares, for an aggregate purchase price of $100. The Underwriters Warrant agreement is exercisable, in whole or in part, commencing on a date which is one (1) year after the effective date of the Registration Statement and expiring on the five-year anniversary of the effective date of the Registration Statement at an initial exercise price per share of Common Stock of $9.0625, which is equal to 125% of the initial public offering price of the Firm Shares.
	Convertible Promissory Notes
	In October 2013, the Company issued an aggregate $1,850,000 principal amount of Notes that bear interest at 7% per annum. Concurrently with the closing of the public offering, such Notes and related accrued interest automatically converted into 256,119 shares of common stock.
	Agreement of Merger – Concortis
	On November 11, 2013, the Company and Catalyst Merger Sub, Inc., a wholly owned subsidiary of the Company, Concortis Biosystems, Corp. (“Concortis”) and Zhenwei Miao and Gang Chen entered into an Agreement of Merger pursuant to which, at the effective time of the merger, the Company will issue an aggregate of 1,331,978 shares of its common stock to the shareholders of Concortis (the “Concortis Merger Shares”) and Catalyst Merger Sub will merge into Concortis (the “Concortis Merger”). Pursuant to the merger agreement, 15% of the Concortis Merger Shares will be held by the Company for any potential indemnification claims.
	In connection with the merger, the Company agreed to appoint Dr. Zhenwei (“David”) Miao, the former President and Chief Scientific Officer of Concortis, as its Chief Technical Officer. In addition, Dr. Miao and certain other employees of Concortis are to receive annual supplemental cash bonus payments totaling $1,000,000 on December 31 of each of the years ending 2013, 2014, 2015, and 2016.

Nature_of_Operations_Summary_o1

Nature of Operations, Summary of Significant Accounting Policies and Business Activities (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Nature of Operations and Basis of Presentation	'
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc., together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the United States, Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including inflammation, metabolic disorders, and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor, as well as fully human therapeutic antibodies derived from our proprietary G-MAB® library platform and antibody drug conjugates, or ADCs, antibody formulated drug conjugates, or AfDCs, and recombinant intravenous immunoglobulin, or rIVIG. See Note 7.
	Through September 30, 2013, the Company had devoted substantially all of its efforts to product development, acquiring companies and in-licensing assets, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	The accompanying interim consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations and cash flows in accordance with generally accepted accounting principles in the U.S., or GAAP.
	The balance sheet at December 31, 2012 is derived from the audited consolidated balance sheet at that date which is not presented herein.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of financial position, results of operations and cash flows. These consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. Operating results for interim periods are not expected to be indicative of operating results for the Company’s 2013 fiscal year.
Reverse Stock Split	'
	Reverse Stock Split
	On July 30, 2013, the Company completed a 1-for-25 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action.
Business Activities	'
	Business Activities
	On September 21, 2009, QuikByte Software, Inc., a shell company (QuikByte) acquired Sorrento Therapeutics, Inc., a privately held Delaware corporation (STI), in a reverse merger (the “Reverse Merger”). Pursuant to the Reverse Merger, all of the issued and outstanding shares of STI common stock were exchanged into an aggregate of 6,775,032 shares of QuikByte common stock and STI became a wholly owned subsidiary of QuikByte. The holders of QuikByte’s common stock as of immediately prior to the Reverse Merger held an aggregate of 2,228,332 shares of QuikByte’s common stock. STI and QuikByte reincorporated in Delaware in December 2009, and on December 4, 2009, STI merged with and into QuikByte, the separate corporate existence of STI ceased and QuikByte continued as the surviving corporation. Contemporaneously, QuikByte Software, Inc. changed its name to Sorrento Therapeutics, Inc. In connection with the Reverse Merger, the Company received cash of $104,860.
	In January 2013, the Company entered into an assignment agreement (the “assignment agreement”) with Tien-Li Lee, M.D. and Jane Wu Lee, M.D. as individuals (collectively, the “Lees”) pursuant to which the Lees agreed to assign to the Company their right, title and interest throughout the world in and to certain inventions and patents that provide for the production of recombinant intravenous immunoglobulins. See Note 2.
	On March 7, 2013, the Company entered into various agreements with IgDraSol, Inc. (“IgDraSol”) a private company focused on the development of Cynviloq, an oncologic agent for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers, as follows: (i) an exclusive option agreement, (ii) an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies, and (iii) an initial services agreement, pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform. See Note 3.
Liquidity	'
	Liquidity
	As reflected in the accompanying consolidated financial statements, the Company has incurred operating losses since its inception in 2006, and as of September 30, 2013, had an accumulated deficit of $21,565,695. At September 30, 2013, the Company had working capital of $4,555,365.
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) advances its CynviloqTM asset into a registration trial (a single bioequivalence study) and pursues other potential indications, (ii) acquires Sherrington Pharmaceuticals, Inc., or Sherrington, and advances its pain drug into clinical trials, (iii) continues to identify and advance a number of fully human therapeutic antibody and ADC preclinical drug candidates, (iv) acquires Concortis Biosystems, Corp., or Concortis, and (v) expands its corporate infrastructure, including the costs associated with being a public company. See Note 7.
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. Contemporaneously with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. In October 2013, the Company: (i) closed an underwritten public offering of 4,772,500 shares of its common stock, including the Underwriters exercise of an over-allotment of 622,500 shares of common stock, at $7.25 per share and total gross proceeds of $34.6 million, and (ii) issued an aggregate $1,850,000 principal amount of Convertible Promissory Notes (the “Notes”) that bear interest at 7% per annum. Such Notes and related accrued interest automatically converted into 256,119 shares of common stock at $7.25 per share effective in October 2013. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months. See Note 7.
	The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the October 2013 underwritten offering, the Company has the ability to offer up to $65.4 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Principles of Consolidation	'
	Principles of Consolidation
	The financial statements also include the accounts of the Company’s wholly-owned subsidiaries, IgDraSol, Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong. Sorrento Hong Kong had no operating activity through September 30, 2013. All inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. Such adjustments could include, for example, appropriate estimates for Company bonus plans normally determined or settled at year-end.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2013 and December 31, 2012, the carrying amount of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Grants Receivable	'
	Grants Receivable
	Grants receivable at September 30, 2013 and December 31, 2012 represent amounts due under federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health (“NIH”), collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. Such lives vary from three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset.
Intangibles	'
	Intangibles
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. The Company had no patent rights as of December 31, 2012. Amortization expense for the three and nine months ended September 30, 2013 was $1,250 and $2,500, respectively, which has been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. The Company had no licenses rights as of December 31, 2012. Amortization expense for the three and nine months ended September 30, 2013 was $110,839, which has been included in intangibles amortization.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through September 30, 2013.
Income Taxes	'
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually.
Revenue Recognition	'
	Revenue Recognition
	The Company’s revenues are generated from the NIH and U.S. Treasury grant awards and a feasibility study agreement, or the Collaboration Agreement, that the Company entered into with a third party in July 2010. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	The revenue from the Collaboration Agreement is derived from the completion of certain development services and the reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue.
Research and Development Costs and Collaborations	'
	Research and Development Costs and Collaborations
	Research and development costs are charged to expense as incurred. Such costs primarily consist of discovery research, pre-clinical activities, manufacture of drug supply, lab supplies, contract and acquired services, stock-based compensation expense, salaries and related benefits, depreciation and allocated and direct facility expenses.
	The Company evaluates its collaborative agreements for proper income statement classification based on the nature of the underlying activity. If payments to collaborative partners are not within the scope of other authoritative accounting literature, the income statement classification for these payments is based on a reasonable, rational analogy to authoritative accounting literature that is applied in a consistent manner. Amounts due to collaborative partners related to development activities are reflected as a research and development expense.
Acquired In-Process Research and Development Expense	'
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.
Stock-based Compensation	'
	Stock-based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity-based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at estimated fair value as they vest.
Net Loss per Share	'
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. No dilutive effect was calculated for the three or nine months ended September 30, 2013 and 2012 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. The Company had outstanding common share equivalents of 551,850 and 460,668 at September 30, 2013 and 2012, respectively. The Company excludes the potential issuance of common shares contingently issuable to the Lees or IgDraSol as there is no guarantee that such shares will be issued in the future. See Notes 2 and 3.
New Accounting Standards	'
	New Accounting Standards
	In July 2012, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update, or ASU, 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment (the revised standard). The objective of this ASU is to simplify how entities test indefinite-lived intangible assets other than goodwill for impairment. The amendments in the ASU provide the option to first assess qualitative factors to determine whether, as a result of its qualitative assessment, that it is more-likely-than-not (a likelihood of more than 50%) the asset is impaired and it is necessary to calculate the fair value of the asset in order to compare that amount to the carrying value to determine the amount of the impairment, if any. If an entity believes, as a result of its qualitative assessment, that it is not more-likely-than-not (a likelihood of more than 50%) that the fair value of an asset is less than its carrying amount, no further testing is required. The revised standard includes examples of events and circumstances that might indicate that the indefinite-lived intangible asset is impaired. The approach in the ASU is similar to the guidance for testing goodwill for impairment contained in ASU 2011-08, intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment. The revised standard, which may be adopted early, is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012 and does not change existing guidance on when to test indefinite-lived intangible assets for impairment. The adoption of the provisions of this guidance is not expected to have a material impact on the Company’s consolidated results of operations, cash flows, and financial position.

IgDraSol_Transactions_and_Acqu1

IgDraSol Transactions and Acquisition (Tables)	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Summary of Purchase Price	'
	The purchase price is summarized as follows:
		(in thousands)
	Cash buyout of certain holders of IgDraSol common stock options and warrants	$	356.1
	Market value of shares of Sorrento common stock issued in exchange for IgDraSol common stock		27,811.40
	Transaction fees, including separation and bonus payments of $771,000 made to IgDraSol employees		937.8
	Total purchase price	$	29,105.30
Summary of Purchase Price Allocation Based on Fair Value of Assets Acquired and Liabilities Assumed	'
	The purchase price has been allocated based on the fair value of assets acquired and liabilities assumed ($ in thousands):
	Assets acquired:
	Cash	$	125.8
	Prepaid expenses & other		44.9
	PP&E		120.9
	Intangible license rights		29,105.30
	Total assets		29,396.90
	Liabilities assumed:
	Accounts payable		167.7
	Accrued expenses		123.9
	Total liabilities		291.6
	Total purchase price	$	29,105.30

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Future Annual Principal Payments under Loan Agreement	'
	Future annual principal payments under the loan agreement, as of September 30, 2013, are as follows:
	2014	$	303,406
	2015		1,907,040
	2016		2,064,298
	2017		725,256
	Debt discount		(214,680	)
	Long-term debt	$	4,785,320

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Fair Value of Employee Stock Options	'
	The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Nine months ended September 30,
		2013			2012
	Dividend yield		—		—
	Volatility		109	%	102%
	Risk-free interest rate		1.19	%	0.71% - 1.11%
	Expected life of options		6.1 years		5.6 years

Nature_of_Operations_Summary_o2

Nature of Operations, Summary of Significant Accounting Policies and Business Activities - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Jul. 31, 2013

Apr. 30, 2013

Sep. 30, 2013

Feb. 28, 2013

Dec. 31, 2012

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Oct. 31, 2013

Oct. 09, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Ratio

Patents [Member]

Patents [Member]

Patents [Member]

License Rights [Member]

License Rights [Member]

License Rights [Member]

Equipment [Member]

Subsequent Events [Member]

Subsequent Events [Member]

QuikByte [Member]

Maximum [Member]

Minimum [Member]

Bank

Patents

Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse split of common stock

'

'Company's common stock by a ratio of not less than 1-for-2 and not more than 1-for-150

'Company completed a 1-for-25 reverse split of its common stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split, common stock

'

'

0.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate of common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

6,775,032

'

'

Common stock, shares outstanding

'

'

16,479,734

'

12,004,687

'

'

'

'

'

'

'

'

'

'

2,228,332

'

'

Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$104,860,000

'

'

Accumulated deficit

'

'

21,565,695

'

10,950,299

'

'

'

'

'

'

'

'

'

'

'

'

'

Working capital

'

'

4,555,365

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of Loan Agreement

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of banks provided Term Loan

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equipment loan balance outstanding

'

'

'

'

'

'

'

'

'

'

'

'

762,361

'

'

'

'

'

Underwritten public offering shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

4,772,500

'

'

'

'

Underwriters exercise over-allotment

'

'

'

'

'

'

'

'

'

'

'

'

'

622,500

'

'

'

'

Underwriters common stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.25

'

'

'

'

Gross proceeds from common stock underwritten

'

'

'

'

'

'

'

'

'

'

'

'

'

34,600,000

'

'

'

'

Aggregate principal amount of Convertible Promissory Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

1,850,000

'

'

'

'

Bear interest rate

'

'

7.95%

5.15%

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

Convertible shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

256,119

'

'

'

'

Common stock convertible price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.25

'

'

'

'

Stock repurchased on open market at aggregate cost

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwritten offering of additional securities

'

'

'

'

'

'

'

'

'

'

'

'

'

65,400,000

'

'

'

'

Allowance for doubtful amounts

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and equipment useful lives of assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'3 years

Estimated useful lives of assets

'

'

'19 years

'

'

'

'

'

'

'

'15 years

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

1,250

2,500

'

110,839

110,839

'

'

'

'

'

'

'

Number of patent rights

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

License rights outstanding

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Impairment losses of long-lived assets

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Uncertain tax positions

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock outstanding

'

'

551,850

'

'

460,668

'

'

'

'

'

'

'

'

'

'

'

'

Significant_Agreements_and_Con1

Significant Agreements and Contracts - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

92 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

92 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

92 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

92 Months Ended

3 Months Ended

9 Months Ended

92 Months Ended

12 Months Ended

1 Months Ended

31-May-12

Jul. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2010

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Jul. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jun. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2010

Jan. 31, 2013

Collaboration Agreement [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

U.S. Treasury Grants [Member]

Assignment Agreement [Member]

Installment

Collaborative Agreements And Contracts [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Terminate notice of license

'

'

'

'

'60 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent prosecution and maintenance costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$13,418

$5,293

$20,225

$27,861

$147,570

'

'

Period of grant

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'2 years

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

Potential annual award

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

Revenue grant as related costs and expenses incurred

'

'

83,791

134,506

359,451

461,790

1,931,524

223,453

'

0

119,379

600,000

'

'

0

94,707

143,940

265,811

592,717

'

83,791

39,799

215,512

39,799

344,328

'

'

'

'

'

394,480

'

Award of grant received for phase 1

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

600,000

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial award granted

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

Antibody screening services for an upfront cash fee

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

Company's common stock upon achievement of milestones of the Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000

Agreed amount pay to lees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

Monthly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

Number of monthly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

IgDraSol_Transactions_and_Acqu2

IgDraSol Transactions and Acquisition - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		92 Months Ended	9 Months Ended	1 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Apr. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2013
						License Rights [Member]	IgDraSol [Member]	IgDraSol [Member]	IgDraSol [Member]	IgDraSol [Member]
Loans At Acquisition Date [Line Items]	'	'	'	'	'	'	'	'	'	'
Non-refundable lump sum option agreement payment	'	'	'	'	'	'	$200,000	'	'	$356,100
Initial services agreement amount	'	'	'	'	'	'	'	1,000,000	'	'
Purchase price of asset under assets purchase agreement	'	'	'	'	'	'	'	1,210,000	'	'
Operating expenses associated with the development services agreement	3,390,628	1,377,853	10,897,541	3,557,609	23,672,260	'	'	'	875,133	1,721,193
Issuance of common stock in connection with IgDraSol merger, shares	'	'	'	'	'	'	'	'	'	3,006,641
Issuance of common stock in connection with IgDraSol merger, value	'	'	'	'	'	'	'	'	400,000	400,000
Additional shares of common stock issued	'	'	'	'	'	'	'	'	'	1,306,272
Future amortization of intangible assets, annual rate	'	'	'	'	'	$1,900,093	'	'	'	'
Amortization of intangible assets, maturity year	'	'	'	'	'	'2028	'	'	'	'

IgDraSol_Transactions_and_Acqu3

IgDraSol Transactions and Acquisition - Summary of Purchase Price (Detail) (IgDraSol [Member], USD $)	1 Months Ended	9 Months Ended
	Apr. 30, 2013	Sep. 30, 2013
IgDraSol [Member]	'	'
Business Acquisition [Line Items]	'	'
Cash buyout of certain holders of IgDraSol common stock options and warrants	$200,000	$356,100
Market value of shares of Sorrento common stock issued in exchange for IgDraSol common stock	'	27,811,400
Transaction fees, including separation and bonus payments of $771,000 made to IgDraSol employees	'	937,800
Total purchase price	'	$29,105,300

IgDraSol_Transactions_and_Acqu4

IgDraSol Transactions and Acquisition - Summary of Purchase Price (Parenthetical) (Detail) (IgDraSol [Member], USD $)	9 Months Ended
	Sep. 30, 2013
IgDraSol [Member]	'
Business Acquisition [Line Items]	'
Bonus payments to employees	$771,000

IgDraSol_Transactions_and_Acqu5

IgDraSol Transactions and Acquisition - Summary of Purchase Price Allocation Based on Fair Value of Assets Acquired and Liabilities Assumed (Detail) (IgDraSol [Member], USD $)	Sep. 30, 2013
IgDraSol [Member]	'
Assets acquired:	'
Cash	$125,800
Prepaid expenses & other	44,900
PP&E	120,900
Intangible license rights	29,105,300
Total assets	29,396,900
Liabilities assumed:	'
Accounts payable	167,700
Accrued expenses	123,900
Total liabilities	291,600
Total purchase price	$29,105,300

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Feb. 28, 2013
	Bank
Debt Disclosure [Abstract]	'	'
Long-term debt	$4,785,320	$875,888
Fixed rate interest accrued on the initial outstanding advance	7.95%	5.15%
Principal amount of Loan Agreement	5,000,000	'
Number of banks provided Term Loan	2	'
Term Loan maturity date	15-Apr-17	'
Warrant received to purchase aggregate of common stock - shares	31,250	'
Warrant received to purchase aggregate of common stock - exercise price	$8	'
Exercisable period for warrants	'7 years	'
Debt discount	214,680	'
Minimum percentage of pre-payment fees	1.00%	'
Maximum percentage of pre-payment fees	3.00%	'
Final fee	$200,000	'

Debt_Future_Annual_Principal_P

Debt - Future Annual Principal Payments under Loan Agreement (Detail) (USD $)	Sep. 30, 2013	Feb. 28, 2013
Debt Disclosure [Abstract]	'	'
2014	$303,406	'
2015	1,907,040	'
2016	2,064,298	'
2017	725,256	'
Debt discount	-214,680	'
Long-term debt	$4,785,320	$875,888

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock and Related Party Transaction) (Detail) (USD $)	1 Months Ended			9 Months Ended				1 Months Ended
	Apr. 30, 2013	Jan. 31, 2013	31-May-12	Sep. 30, 2013	Dec. 31, 2012	Apr. 26, 2013	Apr. 26, 2013	31-May-12	Dec. 31, 2011	Mar. 31, 2013
						Minimum [Member]	Maximum [Member]	Hongye SD Group LLC [Member]	Stock Purchase Agreement [Member]	Private Placement Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Issuance of common stock for cash, net of issuance costs, shares	'	'	1,500,000	'	'	'	'	250,000	500,000	1,426,406
Per share value	'	'	$4	'	'	'	'	'	$4	$4.50
Aggregate gross proceeds	'	'	$6,000,000	'	'	'	'	'	$2,000,000	$6,418,495
Number of shares issued for purchase of patent rights	'	10,000	'	'	'	'	'	'	'	'
Value of common stock issued for purchase of patent rights	'	$40,000	'	'	'	'	'	'	'	'
Common stock, shares authorized	'	'	'	750,000,000	750,000,000	500,000,000	750,000,000	'	'	'
Reverse stock split	'Company's common stock by a ratio of not less than 1-for-2 and not more than 1-for-150	'	'	'Company completed a 1-for-25 reverse split of its common stock.	'	'	'	'	'	'

Stockholders_Equity_Stock_Ince

Stockholders' Equity (Stock Incentive Plans) (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

89 Months Ended

92 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

31-May-12

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2009

Sep. 30, 2013

Feb. 28, 2009

Jan. 31, 2011

Sep. 30, 2013

Sep. 30, 2009

Sep. 30, 2013

Sep. 30, 2012

Apr. 26, 2013

Sep. 30, 2013

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Non-Employee Director Grants [Member]

2009 Non-Employee Director Grants [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

Unvested Restricted Stock [Member]

Stock Option [Member]

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'

'

400,000

'

'

8,000

'

'

'

'

Restricted stock issued to consultants under 2009 equity incentive plan

'

'

'

'

'

'

'

'

296,155

'

'

'

'

'

'

'

'

'

Aggregate gross proceeds

$6,000,000

'

'

'

'

'

'

'

$291

'

'

'

'

'

'

'

'

'

Unvested shares of restricted common stock repurchased by the company

'

'

'

'

'

'

'

'

'

'

'

44,166

'

'

'

'

'

'

Price per share of unvested shares of restricted common stock repurchased by the company

'

'

'

'

'

'

'

'

'

'

'

$43

'

'

'

'

'

'

Restricted shares vesting period under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'4 years

Shares Available for Further Grant under 2009 Non-Employee Director Grants

'

'

'

'

'

'

'

'

'

0

'

'

0

'

833,400

147,800

'

'

Outstanding options vesting anniversary period

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

Minimum exercisable term for stock options

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

Maximum term of options granted under stock plan

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'10 years

'

'

'

Option outstanding

'

'

'

'

'

'

'

'

'

'

'

'

3,200

'

'

'

'

'

Common stock, shares authorized

'

750,000,000

'

750,000,000

'

750,000,000

750,000,000

750,000,000

'

'

'

'

'

'

'

'

1,360,000

'

Employee option grants vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

2009 Stock Incentive Plan common stock reserved for issuance description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In addition, this amount will be automatically increased annually on the first day of each fiscal year by the lesser of: (i) 1% of the aggregate number of shares of the Company's common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 200,000 shares, or (iii) an amount approved by the administrator of the Stock Plan.

'

'

'

Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

Number of shares for increase in shares reserved for issuance under stock plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

Stock options vesting rights under 2009 stock incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Employee option grants will generally vest 25% on each anniversary of the original vesting date over four years.

Options awarded to employees and consultant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,200

325,200

'

'

Weighted average fair value per share of employee stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.78

$3.25

'

'

Employee stock-based compensation recorded as operating expenses

'

157,853

20,685

454,324

75,350

873,140

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to the employee options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,654,334

'

'

'

Period for recognized compensation cost

'

'

'

'2 years 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Based Compensation for Nonemployees

'

$34,254

$66,130

$167,447

$214,722

'

$1,215,270

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) (Employee Stock Option [Member])	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Dividend yield	'	'
Volatility	109.00%	102.00%
Risk-free interest rate	1.19%	'
Expected life of options	'6 years 1 month 6 days	'5 years 7 months 6 days
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	'	0.71%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	'	1.11%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	9 Months Ended		1 Months Ended		0 Months Ended
	Sep. 30, 2013	Feb. 28, 2013	Oct. 31, 2013	Oct. 09, 2013	Nov. 11, 2013	Sep. 30, 2013	Oct. 31, 2013
			Subsequent Events [Member]	Subsequent Events [Member]	Subsequent Events [Member]	Subsequent Events [Member]	Subsequent Events [Member]
					Concortis Biosystems, Corp. [Member]	Concortis Biosystems, Corp. [Member]	Underwritten Public Offering [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Common stock, shares issued	'	'	'	200,000	1,331,978	'	'
Shares are being held in escrow	'	'	'	29,350	'	'	'
Underwritten public offering in aggregate of common stock, shares	'	'	4,772,500	'	'	'	4,150,000
Underwriters common stock price per share	'	'	$7.25	'	'	'	'
Underwriters exercise over-allotment	'	'	622,500	'	'	'	'
Gross proceeds from common stock underwritten	'	'	$34,600,000	'	'	'	'
Purchase of aggregate of shares of common stock	182,600	'	'	'	'	'	'
Percentage of repurchase of common stock	4.40%	'	'	'	'	'	'
Aggregate purchase price	$100	'	'	'	'	'	'
Warrant rights expiration period	'5 years	'	'	'	'	'	'
Initial exercise price of warrants	9.0625	'	'	'	'	'	'
Percentage of exercise price of warrants is equal to initial public offering price	125.00%	'	'	'	'	'	'
Aggregate principal amount of Convertible Promissory Notes	'	'	1,850,000	'	'	'	'
Debt instrument interest rate	7.95%	5.15%	7.00%	'	'	'	'
Debt converted into common stock	'	'	256,119	'	'	'	'
Annual supplemental cash bonus payment	'	'	'	'	'	$1,000,000	'
Percentage of shares held	'	'	'	'	15.00%	'	'